|
Acquired aplastic anemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Our results indicate that genetic ATG5 variants contributed to AA, which may facilitate further clarifying the underlying mechanisms of AA and making a patient-tailored medical decision.
|
30767262 |
2019 |
|
Acute Erythroblastic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we have demonstrated that hemin (a physiological erythroid maturation stimulator) is able to induce the expression of critical autophagic genes (i.e., Map1a1b (LC3), Beclin-1 gen, Atg5) in an erythroleukemia cell type.
|
26773440 |
2016 |
|
Acute lymphocytic leukemia
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Thrombotic events (TEs) are serious secondary complications in children with acute lymphoblastic leukemia (ALL) who receive L-asparaginase (ASP) therapy; however, the prevalence of TEs has not been established.
|
12518376 |
2003 |
|
Acute lymphocytic leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
Asparaginase (ASP) is a cornerstone in the treatment of acute lymphoblastic leukemia (ALL).
|
28440015 |
2017 |
|
Acute lymphocytic leukemia
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
ASP and ATIII activity was measured in 76 children with ALL treated according to the ALL IC BFM 2002 protocol.
|
28060110 |
2017 |
|
Acute lymphocytic leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to investigate the growth inhibition effects of GA in combination with asparaginase (ASP), as a component of combination chemotherapy, in a lymphoblastic leukemia cell line.
|
29217160 |
2017 |
|
Acute lymphocytic leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
Native vs. PEG-ASP administered according to availability in each center were prospectively evaluated in adults with high-risk ALL.
|
29165013 |
2018 |
|
Acute lymphocytic leukemia
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Patients with GRIA1 rs4958351 AA/AG genotype showed significantly reduced risk to ASP hypersensitivity compared to patients with GG genotype in the T-cell ALL subgroup (OR = 0.05 (0.01-0.26); p = 4.70E-04), while no such association was found in pre-B-cell ALL.
|
26457809 |
2015 |
|
Acute Promyelocytic Leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
To determine the role of autophagy in the differentiation of APL, we knocked down ATG5 in NB4 cells to find that ATRA-induced differentiation is significantly inhibited during ATG5 knock down in cells, indicating the role of autophagy in differentiation of APL.
|
30806286 |
2019 |
|
Acute Promyelocytic Leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Distinct TP73-DAPK2-ATG5 pathway involvement in ATO-mediated cell death versus ATRA-mediated autophagy responses in APL.
|
28978663 |
2017 |
|
Acute respiratory distress
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
AJs: adherens junctions; ALI: acute lung injury; ARDS: acute respiratory distress syndrome; ATG5: autophagy related 5; ATG12: autophagy related 12; ATG 16L1: autophagy related 16 like; 1 BALF: bronchoalveolar lavage fluidCQ: chloroquine; Ctrl: control; EC: endothelial cell; GFP: green fluorescent protein; HA-tagged; RAB26<sup>WT</sup>: HA-tagged wild-type; RAB26 HA-tagged; RAB26<sup>QL</sup>: HA-tagged; RAB26<sup>Q123L</sup>HA-tagged; RAB26<sup>NI</sup>: HA-tagged; RAB26<sup>N177I</sup>HPMECs: human pulmonary microvascular endothelial cells; H&E: hematoxylin & eosin; IgG: immunoglobulin; GIF: immunofluorescence; IP: immunoprecipitationi;. p.: intraperitoneal; LPS: lipopolysaccharide; PBS: phosphate-buffered salinesi; RNA: small interfering;RNASQSTM1/p62, sequestosome; 1TBS: Tris-buffered saline; VEGF: vascular endothelial growth factor; WB: western blot; WT: wild-type.
|
29965781 |
2018 |
|
Acute-On-Chronic Liver Failure
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Mfn2 improved the expressions of LC3-II, Atg5 and Bcl-2 and down-regulated the expression of P62 and Bax in ACLF.
|
31557386 |
2019 |
|
Addictive Behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Chronic morphine exposure caused Atg5 (autophagy-related 5)- and Atg7 (autophagy-related 7)-dependent and dopaminergic neuron-specific autophagy resulting in decreased neuron dendritic spines and the onset of addictive behaviors.
|
28722508 |
2017 |
|
Adenocarcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
An impaired autophagy took place at the stage of formation of ATG-5-ATG-12-ATG-16 complex in both gastric carcinoids and adenocarcinoma of both rodent models and patients.
|
23389729 |
2013 |
|
Adenocarcinoma Of Esophagus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Similar chimeric transcripts encoding portions of the MET oncogene and the BCAS3 gene also were overexpressed in EAs, suggesting that L1-5'ASP activation may occur at a broad level in primary EAs.
|
16320248 |
2006 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Importantly, abolishing autophagy using inhibitors and ATG5 siRNA enhanced the cytotoxicity of compound 8b, indicating the cytoprotective role of autophagy in lung adenocarcinoma.
|
29433677 |
2018 |
|
Adenocarcinoma, Oxyphilic
|
0.010 |
Biomarker
|
disease |
BEFREE |
Remarkably, inhibition of autophagosome formation by Atg5 silencing or treatment with pharmacological inhibitors of autophagosome formation restored ciliogenesis in the Hürthle cell carcinoma cell line XTC.UC1 which exhibits a high basal autophagic flux.
|
27816963 |
2016 |
|
Adenoid Cystic Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In summary, Beclin 1 and ATG5 play important roles in regulating both Obatoclax-induced autophagy and apoptosis in adenoid cystic carcinoma.
|
25482163 |
2015 |
|
Adenoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Early treatment of Apc(Min/+)ATG5(+/-) mice with IFN-γ decreased tumor incidence rate to 16.7% and reduced the number of adenomas by 95.5% and late treatment led to regression of tumor.
|
25695667 |
2015 |
|
Adult Acute Lymphocytic Leukemia
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
ASP and ATIII activity was measured in 76 children with ALL treated according to the ALL IC BFM 2002 protocol.
|
28060110 |
2017 |
|
Adult Acute Lymphocytic Leukemia
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Thrombotic events (TEs) are serious secondary complications in children with acute lymphoblastic leukemia (ALL) who receive L-asparaginase (ASP) therapy; however, the prevalence of TEs has not been established.
|
12518376 |
2003 |
|
Adult Acute Lymphocytic Leukemia
|
0.040 |
Biomarker
|
disease |
BEFREE |
Native vs. PEG-ASP administered according to availability in each center were prospectively evaluated in adults with high-risk ALL.
|
29165013 |
2018 |
|
Adult Acute Lymphocytic Leukemia
|
0.040 |
Biomarker
|
disease |
BEFREE |
Asparaginase (ASP) is a cornerstone in the treatment of acute lymphoblastic leukemia (ALL).
|
28440015 |
2017 |
|
Adult Erythroleukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we have demonstrated that hemin (a physiological erythroid maturation stimulator) is able to induce the expression of critical autophagic genes (i.e., Map1a1b (LC3), Beclin-1 gen, Atg5) in an erythroleukemia cell type.
|
26773440 |
2016 |
|
Adult Glioblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
While ATG5 disruption inhibited autophagy, it did not change the phenotypes of glioma cells and did not alter their sensitivity to temozolomide, an agent used for glioblastoma patient therapy.
|
29902340 |
2018 |